Should I Get The RSV Vaccine?

Respiratory Syncytial Virus (RSV) is a seasonal virus that is highly contagious and a common cause of lower respiratory illness that can cause life-threatening pneumonia and bronchiolitis.

On May 23, 2023, the first vaccine, Arexvy, was approved by the US Food and Drug Administration (FDA) for individuals 60 years and older in the United States.

The FDA also approved a second vaccine, Abrysvo. Both work by eliciting an immune response that can protect you if RSV infects you in the future.

Both Arexvy and Abrysvo are a single dose and should be administered before the onset of fall and winter RSV season.

The CDC recommends RSV vaccination for Adults 60 years and older with the following risk factors for developing severe RSV:

• Persons with chronic medical conditions such as heart or lung disease, kidney disorders, liver disorders, or neurological conditions.

• Persons with moderate or severe immune compromise from illness or medications.

• Persons who live in nursing homes and other long-term care facilities who are at risk of developing severe respiratory disease are also included in this list.

The vaccine’s efficacy is still being evaluated regarding how long it protects against RSV and whether additional doses will be needed.

Talk to your Healthcare Provider and discuss the possible adverse reactions and if you have any contraindications to the vaccines.

Vaccines are available at some private doctor's offices, pharmacies, and health departments.